Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3505 DRD2 agonist cabergoline abolished the escape mechanism induced by mTOR inhibitor everolimus in pituitary neuroendocrine tumoral cells

Introduction: The mTOR inhibitor everolimus displays antimitotic effects on diverse neoplasms, including pituitary neuroendocrine ones (PitNETs); however, its effect is reduced by an escape mechanism that increases AKT phosphorylation (p-AKT) leading to survival pathway activation. Dopamine receptor type 2 (DRD2) reduces p-AKT in some non-functioning PitNETs (NF-PitNETs) and in lactotrophs MMQ cells, through a β-arrestin2-dependent mechanism.

Conference:

Presenting Author:

Authors: Mangili F, Esposito E, Treppiedi D, Catalano R, Marra G,

Keywords: pituitary neuroendocrine tumor, everolimus, mTOR/AKT pathway, β-arrestin 2, dopamine receptor type 2, cabergoline,

#2271 Effects of Multi-Receptor Targeting Drugs in Neuroendocrine Tumors Using 3D Cell Culture

Introduction: Symptom control in functioning neuroendocrine tumors(NETs) may be difficult in some cases, thus, new therapeutic options, including multi-receptor targeting drugs are required.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martínez A

Authors: Herrera-Martínez A, Van Dungen R, Van Koetsveld P, Dogan-Oruc F, Culler M,

Keywords: NETs, somatostatin receptors, dopamine receptors, multi-receptor targeting drugs, hormone secretion,

#1581 Evaluation of Somatostatin and Dopamine Receptor Subtype 2 Expression in Pancreatic Neuroendocrine Neoplasms

Introduction: Although somatostatin receptor subtype 2 (SSTR2) and dopamine type 2 receptor (D2R) are reported to be expressed in neuroendocrine neoplasms (NEN), there is a lack of data from studies on a large number of patients with pancreatic NEN.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lee L

Authors: Lee L, Ito T, Kawabe K, Otsuka T, Nakamura M,

Keywords: Somatostatin receptor, dopamine receptor, SSTR2, D2R,

#919 Effect of Combined Treatment with mTOR Inhibitors (mTORi) and Dopamine Agonists on Cell Proliferation in a Human Typical Lung Carcinoid Cell Line

Introduction: The mTOR pathway and dopamine receptors are potential targets for treatment of neuroendocrine tumors (NET).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Sarnataro M

Authors: Sarnataro M, Pivonello C, De Martino M, Sciammarella C, Cuomo G,

Keywords: mTOR, dopamine,

#819 Immunohistochemical and Genomic Evidence for the Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids

Introduction: Expression of somatostatin receptors (SSTRs) and dopamine receptor 2 (DR2) in neuroendocrine tumors is of clinical importance, as they represent potential targets for diagnosis and treatment.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Kanakis G, Grimelius L, Spathis A, Tringidou R, Rassidakis G,

Keywords: lung, carcinoid, somatostatin ,